Duvelisib, a PI3K‐targeted inhibitor that inhibits p110δ and p110γ activity, has been approved for the treatment of relapsed/refractory chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).21 This evidence concerns the gene PIK3CD and B-cell chronic lymphocytic leukemia.